Merck Sharp Dohme Company Profile

What is the competitive landscape for MERCK SHARP DOHME

MERCK SHARP DOHME has twenty approved drugs.

There are twenty US patents protecting MERCK SHARP DOHME drugs.

Summary for Merck Sharp Dohme

US Patents:	20
Tradenames:	16
Ingredients:	16
NDAs:	20

Drugs and US Patents for Merck Sharp Dohme

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No	9,493,582		Y
Merck Sharp Dohme	PREVYMIS	letermovir	SOLUTION;INTRAVENOUS	209940-001	Nov 8, 2017		RX	Yes	Yes	RE46791		Y	Y
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-004	Sep 18, 2012		DISCN	Yes	No	7,326,708*PED				Y
Merck Sharp Dohme	MINTEZOL	thiabendazole	SUSPENSION;ORAL	016097-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Merck Sharp Dohme	PREVYMIS	letermovir	TABLET;ORAL	209939-002	Nov 8, 2017		RX	Yes	Yes

Expired US Patents for Merck Sharp Dohme

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-005	Dec 17, 1998	6,689,761
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-004	Sep 18, 2012	8,168,637
Merck Sharp Dohme	PREVYMIS	letermovir	TABLET;ORAL	209939-002	Nov 8, 2017	8,513,255
Merck Sharp Dohme	PREVYMIS	letermovir	SOLUTION;INTRAVENOUS	209940-002	Nov 8, 2017	7,196,086
Merck Sharp Dohme	TEMODAR	temozolomide	POWDER;INTRAVENOUS	022277-001	Feb 27, 2009	7,786,118

Paragraph IV (Patent) Challenges for MERCK SHARP DOHME drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	100 mg/10 mg and 100 mg/40 mg		2012-06-19
	Tablets	50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg		2012-11-06
	Oral Suspension	40 mg/mL		2011-02-28
	Injection	18 mg/mL, 16.7 mL vials		2015-11-24
	Tablets	100 mg/10 mg and 100 mg/40 mg		2012-06-25
	Capsules	140 mg and 180 mg		2008-03-24
	Delayed-release Tablets	100 mg		2014-06-16

International Patents for Merck Sharp Dohme Drugs

Country	Patent Number	Estimated Expiration
Singapore	11202104208R
Croatia	P20120066
South Korea	20060026061
Chile	2004000930
Croatia	P20191369

Supplementary Protection Certificates for Merck Sharp Dohme Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1622880	LUC00080	Luxembourg		PRODUCT NAME: LETERMOVIR, OU UN SEL, SOLVATE OU SOLVATE DE SON SEL; AUTHORISATION NUMBER AND DATE: /EU/1/17/1245 20180110
1385870	C 2011 014	Romania		PRODUCT NAME: BOCEPREVIR(1R,2S,5S)-N-[3-AMINO-1-(CICLOBUTILMETIL)-2,3-DIOXOPROPIL]-3-[(2S)-2[[[(1,1-DIMETILETIL)AMINO]CARBONIL]AMINO]-3,3-DIMETIL-1-OXOBUTIL]-6,6-DIMETIL-3-AZABICICLO[3.1.0]HEXAN-2-CARBOXAMIDA; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/704/001; DATE OF NATIONAL AUTHORISATION: 20110718; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/704/001; DATE OF FIRST AUTHORISATION IN EEA: 20110718
3494972	LUC00346	Luxembourg		PRODUCT NAME: DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, Y COMPRIS LE DOLUTEGRAVIR SODIQUE, ET LAMIVUDINE; AUTHORISATION NUMBER AND DATE: EU/1/19/1370 20190703
1620113	C300756	Netherlands		PRODUCT NAME: IVERMECTINE VOOR TOEPASSING IN; NAT. REGISTRATION NO/DATE: RVG 115310 20150504; FIRST REGISTRATION: MA117/01101 20150402
1622880	CR 2018 00026	Denmark		PRODUCT NAME: LETERMOVIR, OR ITS SALT, SOLVATE OR SOLVATE OF ITS SALT; REG. NO/DATE: EU/1/17/1245 20180110

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Merck
• Merck And Co Inc
• Merck Kgaa
• Merck Sharp Dohme